ABN 16 165 160 841

ASX RELEASE **27 August 2025**

CEO & Managing Director's Presentation to Annual General Meeting

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to release the CEO & Managing Director's presentation to the Company's Annual General Meeting (YE 31 March 2025) to be held today.

This ASX announcement is authorised for release by the Company Secretary.

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies.

About the ACCENT Trial

The ACCENT trial is entitled '*A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients*'.

The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, determined an optimal dose of narmafotinib (AMP945) by assessing the safety, tolerability, pharmacokinetics and preliminary efficacy when dosed in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer.

The second stage (Phase 2a) of the trial is designed to assess efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and safety and tolerability, with secondary endpoints including Progression Free Survival (PFS), Overall Survival (OS) and Duration on Trial (DOT).

The trial is being conducted at seven sites in Australia and five sites in South Korea.

More information about the ACCENT trial can be found via the ACCENT trial site, the Amplia Therapeutics website and at ClinicalTrials.gov under the identifier NCT05355298.

The Company will provide further updates on the trial as data is accrued.

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn.

Amplia THERAPEUTICS

Annual General Meeting

27 August 2025

Chris Burns PhD GAICD FAHMS

ampliatx.com | @ampliatx

DISCLAIMER

This presentation (**Presentation**) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the **Company** or **Amplia**) which is current as at 30 June 2025. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below.

Summary Information: This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with Amplia's most recent financial report and other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at www.asx.com.au. Subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation.

Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.

Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance.

Future performance and forward-looking statements: This Presentation includes forward looking statements, which can generally be identified by the use of words such as "may", "will", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Amplia's actual results, performance and achievements to differ materially from statements in this Presentation. Forward-looking statements are based on the Company's good faith assumptions as to the financial, market, regulatory and other relevant environments that will exist and affect Amplia's business and operations in the future. The Company does not give any assurance that the assumptions will prove to be correct. There may be other factors that could cause actual results or events not to be as anticipated, and many events are beyond the reasonable control of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements in this Presentation are only made as at the date of this Presentation and the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

Industry data and third party information: Industry data and third party information used in this Presentation may have been obtained from research, surveys, reports or studies conducted by third parties, including industry or general publications. Neither Amplia not its representatives have independently verified any such market or industry data.

Financial Information: This Presentation contains historical financial information based on the Company's results for the 12 month period ending 30 June 2025 and management accounts to 30 June 2025. All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding.

Disclaimer: To the maximum extent permitted by law, Amplia and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement.

EXECUTIVE SUMMARY

Developing a pipeline of small molecule inhibitors of FAK

- Lead drug **narmafotinib** is best-in-class FAK inhibitor in development
- **Promising efficacy, durability and tolerability** in Phase 2a ACCENT clinical trial in pancreatic cancer
- **US trial of narmafotinib** in pancreatic cancer to start imminently
- **FAST-track** and **Orphan Drug Designation** granted from US FDA

COMPANY SUMMARY

ASX: ATX

Share price (26 Aug 2025)	$0.188
Share price range (52 week low/high)	$0.049 - 0.42
Shares on issue	486.48M
Market capitalization (26 Aug 2025)	$91.2M (approx.)

ATX Price and Volume - 12 months

METASTATIC PANCREATIC CANCER

Limited treatment options; poor patient outcomes

5Y Survival



Highly aggressive with multiple genetic drivers

>50% pancreatic cancer patients **diagnosed with advanced** (metastatic, stage 4) disease at the time of diagnosis

Limited Treatment Options

Treatment	Median Progression Free Survival	Median Overall Survival	Tolerability
Gemcitabine + Abraxane® *(MPACT study)*	**5.5 months**	**8.5 months**	😐
FOLFIRINOX *(Prodige study)*	**6.4 months**	**11.1 months**	☹

Most patients receive gemcitabine + Abraxane or FOLFIRINOX or variations of these†



MPACT Trial - *N Engl J Med.* 2013, 369, 1691-703; PRODIGE trial - *N Engl J Med.* 2011, 364, 1817-1825; † - *The Oncologist* 2022, 27, 469–475

THE AMPLIA ADVANTAGE

Three critical features



ACCENT TRIAL TOPLINE DATA

Promising evidence of efficacy, durability and tolerability

Median Progression Free Survival (mPFS) data

- Currently determined at 7.6 months - substantially better than chemotherapy alone (5.5 months)
  - Interim data with 17 patients still on trial
- Improvement over FOLFIRINOX chemotherapy (6.4 months)

	ACCENT Trial (Narmafotinib/Gemcitabine/Abraxane)	MPACT Trial (Gemcitabine/Abraxane)	PRODIGE Trial (FOLFIRINOX)
mPFS	7.6 months	5.5 months	6.4 months

All ACCENT patients @ 400 mg (n = 64)



PFS data calculation included patients from Phase 1b dosed with narmafotinib (400 mg) and all patients in Phase 2a. Interim data based on data cut-off 20 Jul 2025.

ACCENT TRIAL TOPLINE DATA

Promising evidence of efficacy, durability and tolerability

Excellent response rate observed

- **1 confirmed Complete Response**
- **16 confirmed Partial Responses**
  - **Incl. 1 patient** determined to be a **pathological Complete Response**
- Objective response rate (ORR) of 31%
- Disease control rate (DCR) of 73%

Excellent durability observed

- **Duration on Trial far exceeds historical MPACT data**
- **7 patients on study > 1 year**

At data cut-off (20 Jul 2025):

- 17 patients remain on study
- Data for 6 patients at 6 months yet to be collected

	ACCENT Trial (Narmafotinib/Gemcitabine/ Abraxane)	MPACT Trial (Gemcitabine/ Abraxane)
CR	2%	0.2%
PR	29%	23%
SD	42%	27%
PD	16%	20%
NE*	11%	30%
ORR	31%	23%
DCR	73%	50%
DOT	202 days	117 days

Interim data based on data cut-off Jul 20, 2025. Responses are investigator read. * NE - Non-evaluable

ACCENT TRIAL TOPLINE DATA

Promising evidence of efficacy, durability and tolerability

Excellent tolerability observed to date

- Narmafotinib treatment results in negligible extra patient burden

Adverse Events (Grade 3 or above)

Adverse Event (AE) Grade ≥ 3	Narmafotinib +Gem/Abr (ACCENT; N=55)	Gem/Abr (MPACT; N=421)	Gem/Abr (NAPOLI 3; N=379)	FOLFIRINOX (PRODIGE; N=171)	NALIRIFOX (NAPOLI 3; N=370)
Neutropenia	**38.2%**	**38%**	39%	46%	24%
Anemia	**9.1%**	**13%**	18%	8%	11%
Diarrhea	**5.5%**	**6%**	5%	13%	20%
Peripheral neuropathy	**3.6%**	**17%**	6%	9%	3%
Vomiting	**3.6%**	**NR**	2%	15%	7%
Febrile Neutropenia	**5.5%**	**3%**	NR	5%	NR
Thrombocytopenia	**NR**	**13%**	NR	9%	NR
Fatigue	**NR**	**17%**	5%	24%	6%
Hypokalemia	**NR**	**NR**	4%	NR	15%
Nausea	**3.6%**	**NR**	3%	NR	12%

ACCENT and MPACT trials have very similar inclusion criteria and trial designs however no head-to-head clinical trial has been conducted. Differences exist between ACCENT and other trials in design, inclusion criteria and patient demographics. NR - Not Reached. NAPOLI 3 Trial - *The Lancet* 2023, 402(10409),1272-1281

AMPLICITY TRIAL

Phase 1b/2a study in Pancreatic Cancer in the US and Australia

Objective

- To determine safety and efficacy of narmafotinib when added to FOLFIRINOX in newly diagnosed metastatic patients
- To identify recommended phase 2 dose (RP2D)

Primary Endpoints

- Safety, Tolerability
- RP2D

Additional Endpoints

- Objective Response Rate (RECIST v1.1)
- Duration of Response
- Progression free survival (PFS)
- Overall Survival (OS)

Trial Sites

- 2 Australian sites open and recruiting
- 4 US sites in final stages of site initiation

Entry from clinicaltrials.gov/study/NCT07026279



FUTURE OPPORTUNITIES

FAK inhibition will enhance multiple therapeutic strategies

Narmafotinib
(FAK inhibition)

CHEMOTHERAPY
Clinical and preclinical data incl. ACCENT study

IMMUNOTHERAPIES
Preclinical data

KRAS INHIBITORS
Preclinical data, incl. NEXT&BIO collaboration

RADIOTHERAPY
Published data

ANTIBODY DRUG CONJUGATES
Published data

UPCOMING MILESTONES

Q3 2025

ACCENT top-line data

ACCENT request FDA type C meeting - Phase 2b/3 pivotal trial design

AMPLICITY first patient dosed (part A)

ACCENT further patient updates

Q4 2025

ACCENT further patient updates

AMPLICITY first trial data

FDA meeting and minutes **ACCENT** trial pathway

IIT funding outcome(s)

Possible EU regulatory filings

Q1 2026

ACCENT mature data (including OS)

AMPLICITY complete dose escalation

Initiate kRAS combination IIT

EU regulatory response

Q2 2026

ACCENT trial completion possible

AMPLICITY further patient updates

Initiate IIT in ovarian cancer

Drug product scale-up

ACCENT Phase 2b/3 trial protocol finalised

2H 2026

ACCENT full data release

AMPLICITY 2-dose comparison trial begins

IIT data updates (kRAS and Ovarian)

ACCENT Phase 2b/3 trial planning finalised

THANK YOU

Chris Burns PhD GAICD FAHMS
CEO and MD

chris@ampliatx.com

Amplia Therapeutics Limited
ASX: ATX
info@ampliatx.com

ampliatx.com